Shuzhi Dong, Zhiqiang Zhao, Haiqun Tang, Guoqing Li, Jianping Pan, Xin Gu, Jinlong Jiang, Li Xiao, Giovanna Scapin, David N Hunter, Dexi Yang, Yuhua Huang, Frank Bennett, Shu-Wei Yang, Mihirbaran Mandal, Haifeng Tang, Jing Su, Clare Tudge, Reynalda Keh deJesus, Fa-Xiang Ding, Matthew Lombardo, Jacqueline D Hicks, Thierry Fischmann, Asra Mirza, Priya Dayananth, Ronald E Painter, Artjohn Villafania, Charles G Garlisi, Rumin Zhang, Todd W Mayhood, Qian Si, Nianyu Li, Rupesh P Amin, Bhavana Bhatt, Feifei Chen, Christopher P Regan, Hillary Regan, Xinjie Lin, Jin Wu, Andrew Leithead, Scott R Pollack, Jack D Scott, Ravi P Nargund, Alex G Therien, Todd Black, Katherine Young, Alexander Pasternak
The use of β-lactam (BL) and β-lactamase inhibitor combination to overcome BL antibiotic resistance has been validated through clinically approved drug products. However, unmet medical needs still exist for the treatment of infections caused by Gram-negative (GN) bacteria expressing metallo-β-lactamases. Previously, we reported our effort to discover pan inhibitors of three main families in this class: IMP, VIM, and NDM. Herein, we describe our work to improve the GN coverage spectrum in combination with imipenem and relebactam...
February 22, 2024: Journal of Medicinal Chemistry